COR Therapeutics
Executive Summary
Initial public offering of 2 mil. shares of common stock at $ 7.50 per share commenced June 27. The preliminary prospectus had estimated a per share price of $ 9 to $ 11 for 2.5 mil. shares. COR's initial product candidate, the platelet aggregation inhibitor Integrelin, entered Phase I trials in early May.
Initial public offering of 2 mil. shares of common stock at $ 7.50
per share commenced June 27. The preliminary prospectus had
estimated a per share price of $ 9 to $ 11 for 2.5 mil. shares.
COR's initial product candidate, the platelet aggregation inhibitor
Integrelin, entered Phase I trials in early May. |